Loading
Life sciences · Journal article
World Journal of Cardiology · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction-associated steatotic liver disease often coexists with obesity, diabetes, cardiovascular disease, and chronic kidney disease (CKD).However, cardiovascular clinics often do not assess liver fibrosis risk.Incretin-based therapies can reduce cardiovascular events and improve steatohepatitis histology.Sodium-glucose cotransporter 2 inhibitors have hard endpoint benefits in heart failure (HF) and CKD.Combination therapy has only observational signals and lacks prospective validation.This review proposes a fibrosis-4 index based triage to identify three phenotypes: Obesity/metabolic burden, cardiovascular disease, and HF/CKD.Fibrosis stage is used as an independent modifier.